DUX4 and facioscapulohumeral muscular dystrophy: Thus, we encompass the gradual transition of DUX4 over the past 25 years from being considered a pseudogene in “junk DNA” to becoming central to understanding the molecular pathogenesis of FSHD and the primary focus for FSHD therapeutics.